City of Hope Opens Trial Combining Two Immunotherapies
City of Hope and Adagene have opened a Phase 1 trial pairing ivonescimab with muzastotug (ADG126) in up to 36 patients with advanced microsatellite stable colorectal cancer. The investigator-initiated study starts with patients whose disease progressed on prior therapy and tests safety and dose before anything else.
Edited and fact-checked by Stephen Sprague
This is a Phase 1 trial. It tests safety and dose first, and it has not shown that the combination helps anyone yet.
City of Hope and Adagene opened a Phase 1 trial on Tuesday, November 17, 2026, pairing two experimental immunotherapies in advanced colorectal cancer.
The trial will enroll up to 36 patients with metastatic microsatellite stable colorectal cancer, the form that covers about 85 percent of colorectal cases and carries a higher risk of returning after treatment. The principal investigator is Marwan G. Fakih, M.D., a City of Hope professor in the Department of Medical Oncology and Therapeutics Research and deputy director of City of Hope Comprehensive Cancer Center. Dr. Fakih is a paid consultant to Adagene, and the companies disclosed that in the announcement.
Colorectal cancer is the second deadliest cancer in the United States. The American Cancer Society estimates 159,000 Americans will be diagnosed with it this year and about 55,230 will die from it, according to figures the companies cited in the release.
The two drugs attack the cancer from different directions. Ivonescimab targets both PD-1 and VEGF. It activates T cells against cancer cells while it cuts off the blood supply to tumors. Muzastotug, called ADG126, is a masked anti-CTLA-4 antibody built to switch on inside the tumor and limit activity in healthy tissue. It already carries an FDA Fast Track designation in combination with pembrolizumab for a defined group of patients with this cancer type.
The design starts narrow on purpose. The first patients have already progressed on prior systemic therapy, and the team will settle the safest and most effective dose combination before it moves the pairing earlier in treatment. Later steps add 5-FU, the chemotherapy backbone for this cancer, and then irinotecan, a standard first-line and second-line drug.
Readers should hold the evidence boundary where the release puts it. This is a Phase 1, investigator-initiated study. It has produced no results in this combination yet. The strongest prior signal the companies cite is a separate small trial of 22 people where ivonescimab plus chemotherapy produced responses in 82 percent of patients. A 22-person result does not predict what 36 people in a different regimen will show.
What the trial can answer first is practical. Can doctors give both drugs together at a dose patients tolerate, and does the pairing shrink tumors often enough to justify a larger study? Those answers come from this enrollment, not from the announcement.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.